A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer
Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Apr 22, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a program called "patient navigation" to help women who are at high risk for breast cancer better manage their health. Women with a family history of breast cancer often have a higher chance of developing the disease themselves, and there are ways to lower this risk through regular check-ups, preventive surgeries, and medications. However, many women do not take advantage of these options. The patient navigation program aims to provide women with the information and support they need to understand their risk and make informed decisions about their health.
To participate in this trial, women must be between 18 and 75 years old, identify as non-Hispanic Black or non-Hispanic white, and be considered at high risk for breast cancer based on a screening program. They should not have previously been diagnosed with breast or ovarian cancer and should be early in their journey of understanding risk management options. Throughout the trial, participants can expect guidance on navigating the healthcare system, which may include help with scheduling appointments and understanding their risk management choices. This support could help them feel more confident and proactive about their breast health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Are non-Hispanic Black or non-Hispanic white
- • Identify as women
- • Are between 18 and 75 years old
- • Have been identified as at potentially high risk by a population-based risk screening program
- • Have never been diagnosed with breast or ovarian cancer
- • Are early in their risk-management adoption process, defined as currently identifying with stage 0 (never heard of it) or 1 (haven't decided) of the risk-management adoption pathway (R-MAP) in relation to at least one of the four risk-management actions recommended for all high-risk women: attending genetic counseling appointment, having a personalized risk assessment, undergoing annual clinical breast exams, and considering chemoprevention
- • Who do not believe cancer can be prevented and/or have not received risk-management guidance from a specialist
About Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Tasleem J Padamsee, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported